~~<i id='FE5112F2CC'><strike id='FE5112F2CC'><tt id='FE5112F2CC'><pre id='FE5112F2CC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

focus

author：explore 2025-08-19 20:47:30 - browse：345

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met.

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

focus

Wikipedia

leisure time

explore

APSTockThepillworkslikemagic,peoplewho’veuseditsay,toquelltheiranxietyaroundpublicspeaking.Fordecade

WSS

Readers respond to H5N1 and livestock movements, and more

Covid misinformation case heads to Supreme Court

Do digital therapeutics have a future in medicine?

Solving academic medical centers' existential crisis

NVIDIA and Google execs on the future of AI and drug discovery

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

hotspot

focus

focus

Moonlake's readout produced a cash windfall. Risks remain

Second House panel advances two

Medicare details structure of new drug price negotiation program

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Dobbs anniversary: the lost opportunity of abortion as health care

Even great ERs can’t make up for American health disparities

Alkermes shareholders re

Even great ERs can’t make up for American health disparities

Supreme Court strikes down use of affirmative action

Covid misinformation case heads to Supreme Court

focus

Anxious about a speech? A startup wants you to pop a minty cardiac drug

A $475,000 price tag for a new cancer drug: crazy or meh?

Criminal prosecution for violating HIPAA: an emerging threat

FDA drug safety: Singulair case shows systemic surveillance flaws

Medicare drug price negotiation’s day in court

Criminal prosecution for violating HIPAA: an emerging threat

Wikipedia

leisure time

leisure time

explore